交易 BioMarin Pharmaceutical Inc - BMRN CFD
加入收藏夹- 概括
- 曆史數據
- 活動
- 收入報表
- 資産負債表
- 現金流
价差 | 0.15 | ||||||||
多头隔夜费
多头隔夜费
前往平台 | -0.026179% | ||||||||
空头隔夜费
空头隔夜费
前往平台 | 0.003957% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 5% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Biomarin Pharmaceutical Inc ESG Risk Ratings
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 關閉 | 更改 | 變化 (%) | 打開 | 高 | 低 |
---|---|---|---|---|---|---|
Apr 17, 2024 | 90.42 | -0.42 | -0.46% | 90.84 | 91.41 | 89.87 |
Apr 16, 2024 | 90.61 | 0.32 | 0.35% | 90.29 | 91.68 | 89.98 |
Apr 15, 2024 | 91.13 | -0.87 | -0.95% | 92.00 | 93.30 | 90.90 |
Apr 12, 2024 | 92.15 | 1.31 | 1.44% | 90.84 | 93.16 | 90.16 |
Apr 11, 2024 | 91.37 | 1.44 | 1.60% | 89.93 | 91.52 | 89.20 |
Apr 10, 2024 | 90.08 | 2.27 | 2.59% | 87.81 | 90.32 | 87.62 |
Apr 9, 2024 | 88.88 | 2.45 | 2.83% | 86.43 | 89.11 | 86.43 |
Apr 8, 2024 | 87.28 | 1.23 | 1.43% | 86.05 | 88.03 | 85.71 |
Apr 5, 2024 | 86.84 | 0.84 | 0.98% | 86.00 | 87.14 | 85.46 |
Apr 4, 2024 | 86.79 | 0.59 | 0.68% | 86.20 | 87.99 | 85.93 |
Apr 3, 2024 | 86.67 | 0.88 | 1.03% | 85.79 | 87.65 | 85.29 |
Apr 2, 2024 | 86.68 | 1.01 | 1.18% | 85.67 | 86.86 | 85.26 |
Apr 1, 2024 | 87.03 | 0.75 | 0.87% | 86.28 | 87.18 | 86.02 |
Mar 28, 2024 | 87.27 | -0.70 | -0.80% | 87.97 | 88.34 | 86.59 |
Mar 27, 2024 | 88.38 | 0.56 | 0.64% | 87.82 | 88.68 | 87.23 |
Mar 26, 2024 | 87.63 | 1.17 | 1.35% | 86.46 | 87.79 | 86.41 |
Mar 25, 2024 | 86.43 | 1.88 | 2.22% | 84.55 | 86.91 | 84.30 |
Mar 22, 2024 | 85.02 | 1.25 | 1.49% | 83.77 | 85.23 | 83.54 |
Mar 21, 2024 | 84.03 | -0.35 | -0.41% | 84.38 | 85.06 | 83.76 |
Mar 20, 2024 | 84.66 | 0.43 | 0.51% | 84.23 | 85.08 | 83.66 |
BioMarin Pharmaceutical Inc Events
时间(协调世界时) (UTC) | 国家 | 事件 |
---|---|---|
Wednesday, April 24, 2024 | ||
时间(协调世界时) (UTC) 20:00 | 国家 US
| 事件 Q1 2024 Biomarin Pharmaceutical Inc Earnings Release Q1 2024 Biomarin Pharmaceutical Inc Earnings ReleaseForecast(预报) -上一页 - |
时间(协调世界时) (UTC) 20:30 | 国家 US
| 事件 Q1 2024 Biomarin Pharmaceutical Inc Earnings Call Q1 2024 Biomarin Pharmaceutical Inc Earnings CallForecast(预报) -上一页 - |
Tuesday, May 21, 2024 | ||
时间(协调世界时) (UTC) 16:00 | 国家 US
| 事件 Biomarin Pharmaceutical Inc Annual Shareholders Meeting Biomarin Pharmaceutical Inc Annual Shareholders MeetingForecast(预报) -上一页 - |
Wednesday, May 22, 2024 | ||
时间(协调世界时) (UTC) 17:00 | 国家 US
| 事件 Biomarin Pharmaceutical Inc Annual Shareholders Meeting Biomarin Pharmaceutical Inc Annual Shareholders MeetingForecast(预报) -上一页 - |
Monday, July 29, 2024 | ||
时间(协调世界时) (UTC) 20:00 | 国家 US
| 事件 Q2 2024 Biomarin Pharmaceutical Inc Earnings Release Q2 2024 Biomarin Pharmaceutical Inc Earnings ReleaseForecast(预报) -上一页 - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 2096.04 | 1846.28 | 1860.45 | 1704.05 | 1491.21 |
收入 | 2096.04 | 1846.28 | 1860.45 | 1704.05 | 1491.21 |
收入成本,共計 | 483.669 | 470.515 | 524.272 | 359.466 | 315.264 |
毛利 | 1612.37 | 1375.76 | 1336.18 | 1344.58 | 1175.95 |
總營業費用 | 1946.48 | 1928.62 | 1897.22 | 1804.51 | 1614.74 |
銷售/一般/行政費用,總計 | 831.009 | 760.923 | 737.784 | 675.665 | 610.014 |
研究與開發 | 649.606 | 628.793 | 628.116 | 715.007 | 696.328 |
Depreciation / Amortization | 62.8 | 61.9 | 62.2 | 53.5 | 30.3 |
利息費用(收入) - 淨運營 | -1.548 | -0.115 | 5.259 | -5.661 | |
異常費用(收入) | -85 | 0 | -59.495 | -25 | -50 |
Other Operating Expenses, Total | 4.393 | 8.033 | 4.458 | 20.608 | 18.491 |
營業收入 | 149.562 | -82.341 | -36.765 | -100.457 | -123.524 |
利息收入(費用),非經營淨值 | 2.064 | -4.855 | -12.705 | -1.299 | -21.386 |
其他,淨值 | -2.05 | 11.846 | 7.148 | 6.945 | 2.205 |
稅前淨收入 | 149.576 | -75.35 | -42.322 | -94.811 | -142.705 |
稅後淨收入 | 141.561 | -68 | 4.561 | -23.848 | -77.211 |
未計算非常項目前的淨收益 | 141.561 | -68 | 4.561 | -23.848 | -77.211 |
淨收入 | 141.561 | -64.08 | 859.1 | -23.848 | -77.211 |
普通股股東可獲收益 (不含非經常性項目) | 141.561 | -68 | 4.561 | -23.848 | -77.211 |
普通股股東可獲收益 (含非經常性項目) | 141.561 | -64.08 | 859.1 | -23.848 | -77.211 |
攤薄淨收入 | 141.561 | -64.08 | 859.1 | -23.848 | -77.211 |
攤薄後加權平均股 | 188.963 | 182.852 | 191.678 | 179.039 | 177.061 |
扣除特別項目的每股攤薄盈利 | 0.74915 | -0.37189 | 0.0238 | -0.1332 | -0.43607 |
每股正常攤薄盈利 | 0.32343 | -0.37189 | -0.17796 | -0.22396 | -0.61962 |
非常規項目總計 | 3.92 | 854.539 | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 595.275 | 596.415 | 537.538 | 505.344 | 533.798 |
收入 | 595.275 | 596.415 | 537.538 | 505.344 | 533.798 |
收入成本,共計 | 128.082 | 126.549 | 127.29 | 116.288 | 123.126 |
毛利 | 467.193 | 469.866 | 410.248 | 389.056 | 410.672 |
總營業費用 | 536.405 | 537.068 | 562.038 | 507.761 | 494.646 |
銷售/一般/行政費用,總計 | 215.336 | 223.003 | 245.739 | 216.816 | 196.835 |
研究與開發 | 177.363 | 171.846 | 172.751 | 157.829 | 158.19 |
Depreciation / Amortization | 15.6 | 15.7 | 15.7 | 15.9 | 15.6 |
異常費用(收入) | 0 | 0 | 0 | 0 | 0 |
Other Operating Expenses, Total | 0.024 | -0.03 | 0.558 | 0.928 | 0.895 |
營業收入 | 58.87 | 59.347 | -24.5 | -2.417 | 39.152 |
利息收入(費用),非經營淨值 | 8.857 | 8.24 | 5.084 | 0.32 | -1.354 |
其他,淨值 | 3.083 | -10.83 | 1.858 | 0.193 | -2.947 |
稅前淨收入 | 70.81 | 56.757 | -17.558 | -1.904 | 34.851 |
稅後淨收入 | 56.04 | 50.852 | -0.249 | -6.652 | 27.664 |
未計算非常項目前的淨收益 | 56.04 | 50.852 | -0.249 | -6.652 | 27.664 |
淨收入 | 56.04 | 50.852 | -0.249 | -6.652 | 27.664 |
普通股股東可獲收益 (不含非經常性項目) | 56.04 | 50.852 | -0.249 | -6.652 | 27.664 |
普通股股東可獲收益 (含非經常性項目) | 56.04 | 50.852 | -0.249 | -6.652 | 27.664 |
攤薄淨收入 | 56.04 | 50.852 | -0.249 | -6.652 | 27.664 |
攤薄後加權平均股 | 194.998 | 194.363 | 186.037 | 185.597 | 187.448 |
扣除特別項目的每股攤薄盈利 | 0.28739 | 0.26163 | -0.00134 | -0.03584 | 0.14758 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | 0.28739 | 0.26163 | -0.00134 | -0.03584 | 0.14758 |
非常規項目總計 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 2751.46 | 2274.39 | 2342.22 | 1942.14 | 2056.22 |
現金和短期投資 | 1291.54 | 1013.88 | 1065.39 | 753.807 | 1084.31 |
現金等價物 | 724.531 | 587.276 | 649.158 | 437.446 | 493.982 |
短期投資 | 567.006 | 426.599 | 416.228 | 316.361 | 590.326 |
應收賬款總額,淨額 | 461.316 | 373.399 | 448.351 | 377.404 | 342.633 |
應收賬款 - 貿易,淨額 | 461.316 | 373.399 | 448.351 | 377.404 | 342.633 |
總庫存 | 894.083 | 776.669 | 698.548 | 680.275 | 530.871 |
其他流動資産,總計 | 104.521 | 110.442 | 129.934 | 130.657 | 98.403 |
總資産 | 6375.07 | 6003.33 | 5848.02 | 4690.04 | 4427.13 |
物業/廠房/設備,總計 - 淨額 | 1114.32 | 1081.88 | 1089.58 | 1070.3 | 948.682 |
物業/廠房/設備,總計 - 總額 | 1916.47 | 1802.45 | 1725.18 | 1619.4 | 1421.32 |
累計折舊,總計 | -802.145 | -720.574 | -635.595 | -549.1 | -472.635 |
商譽,淨額 | 196.199 | 196.199 | 196.199 | 197.039 | 197.039 |
無形資産,淨額 | 338.569 | 388.652 | 417.271 | 456.58 | 491.808 |
長期投資 | 333.835 | 507.793 | 285.473 | 411.978 | 235.864 |
其他長期資産,總計 | 1640.69 | 1554.42 | 1517.28 | 611.997 | 497.52 |
流動負債總額 | 588.884 | 539.822 | 492.548 | 932.503 | 523.241 |
Payable/Accrued | 231.238 | 193.003 | 191.429 | 240.981 | 208.119 |
預提費用 | 317.834 | 277.059 | 266.254 | 287.878 | 213.03 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
長期債務的當前部分/資本租賃 | 2.287 | 2.266 | 2.865 | 365.131 | 0 |
其他流動負債,總計 | 37.525 | 67.494 | 32 | 38.513 | 102.092 |
負債總額 | 1771.92 | 1732.58 | 1742.02 | 1567.66 | 1459.19 |
長期債務總額 | 1083.2 | 1081.04 | 1079.15 | 492.946 | 830.417 |
長期債務 | 1083.02 | 1079.08 | 1075.15 | 486.238 | 830.417 |
遞延所得稅 | |||||
其他負債,總計 | 99.831 | 111.726 | 170.319 | 142.209 | 105.53 |
總權益 | 4603.16 | 4270.74 | 4106 | 3122.38 | 2967.94 |
普通股 | 0.186 | 0.184 | 0.182 | 0.18 | 0.178 |
額外實收資本 | 5404.9 | 5191.5 | 4993.41 | 4832.71 | 4669.93 |
留存收益(累計赤字) | -789.199 | -925.689 | -861.609 | -1720.71 | -1694.13 |
其他權益,總計 | -0.633 | 6.116 | -29.867 | 6.638 | -6.113 |
總負債和股東權益 | 6375.07 | 6003.33 | 5848.02 | 4690.04 | 4427.13 |
已發行普通股總數 | 186.251 | 183.913 | 181.741 | 179.838 | 178.253 |
Unrealized Gain (Loss) | -12.093 | -1.373 | 3.889 | 3.565 | -1.917 |
資本租賃義務 | 0.184 | 1.96 | 4.006 | 6.708 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 2955.31 | 2950.12 | 2842.1 | 2751.46 | 2682.7 |
現金和短期投資 | 1125.84 | 1170.96 | 1152.09 | 1291.54 | 1273.77 |
現金等價物 | 785.414 | 694.381 | 580.074 | 724.531 | 761.515 |
短期投資 | 340.431 | 476.577 | 572.017 | 567.006 | 512.253 |
應收賬款總額,淨額 | 572.498 | 610.222 | 597.913 | 461.316 | 419.622 |
應收賬款 - 貿易,淨額 | 572.498 | 610.222 | 597.913 | 461.316 | 419.622 |
總庫存 | 1032.16 | 975.546 | 918.921 | 894.083 | 839.46 |
其他流動資産,總計 | 224.806 | 193.391 | 173.18 | 104.521 | 149.851 |
總資産 | 6758.16 | 6563.17 | 6433.69 | 6375.07 | 6264.04 |
物業/廠房/設備,總計 - 淨額 | 1067.16 | 1067.28 | 1068.14 | 1114.32 | 1051.82 |
物業/廠房/設備,總計 - 總額 | 1918.61 | 1896.45 | 1875.09 | 1916.47 | 1834.22 |
累計折舊,總計 | -851.453 | -829.177 | -806.944 | -802.145 | -782.399 |
商譽,淨額 | 196.199 | 196.199 | 196.199 | 196.199 | 196.199 |
無形資産,淨額 | 302.476 | 310.343 | 325.989 | 338.569 | 354.024 |
長期投資 | 548.002 | 385.777 | 340.635 | 333.835 | 372.302 |
其他長期資産,總計 | 1689.02 | 1653.46 | 1660.62 | 1640.69 | 1606.99 |
流動負債總額 | 1163.22 | 597.231 | 598.231 | 588.884 | 521.02 |
Payable/Accrued | 301.369 | 277.944 | 264.778 | 231.238 | 207.165 |
預提費用 | 350.452 | 291.027 | 307.568 | 317.834 | 264.051 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 18.004 | 28.26 | 25.885 | 37.525 | 49.804 |
負債總額 | 1861.27 | 1780.34 | 1774.65 | 1771.92 | 1695.53 |
長期債務總額 | 592.586 | 1084.99 | 1084.01 | 1083.2 | 1082.03 |
長期債務 | 592.586 | 1084.99 | 1084.01 | 1083.02 | 1082.03 |
其他負債,總計 | 105.457 | 98.12 | 92.415 | 99.831 | 92.473 |
總權益 | 4896.9 | 4782.83 | 4659.04 | 4603.16 | 4568.51 |
普通股 | 0.188 | 0.188 | 0.188 | 0.186 | 0.186 |
額外實收資本 | 5542.77 | 5493.96 | 5417.87 | 5404.9 | 5335.85 |
留存收益(累計赤字) | -641.929 | -682.307 | -738.347 | -789.199 | -788.949 |
Unrealized Gain (Loss) | -7.328 | -8.582 | -8.075 | -12.093 | -15.12 |
其他權益,總計 | 3.192 | -20.428 | -12.596 | -0.633 | 36.544 |
總負債和股東權益 | 6758.16 | 6563.17 | 6433.69 | 6375.07 | 6264.04 |
已發行普通股總數 | 188.339 | 188.152 | 187.601 | 186.251 | 185.824 |
長期債務的當前部分/資本租賃 | 493.398 | 2.287 | |||
資本租賃義務 | 0.184 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | 141.561 | -64.08 | 859.1 | -23.848 | -77.211 |
经营活动产生的现金 | 175.902 | 304.536 | 85.365 | 48.262 | 20.208 |
经营活动产生的现金 | 101.969 | 108.039 | 105.172 | 105.3 | 95.671 |
Deferred Taxes | -52.087 | -15.608 | -888.907 | -82.76 | -68.378 |
非现金物品 | 80.842 | 210.151 | 234.417 | 150.662 | 119.546 |
Cash Taxes Paid | 54.372 | 18.153 | 8.977 | 9.726 | 16.676 |
已付现金利息 | 10.281 | 10.395 | 12.178 | 8.552 | 11.623 |
营运资金的变化 | -96.383 | 66.034 | -224.417 | -101.092 | -49.42 |
投资活动产生的现金 | -20.029 | -366.313 | -53.621 | -31.026 | 264.351 |
资本支出 | -131.54 | -119.225 | -137.519 | -163.406 | -144.62 |
其他投资现金流量项目,总计 | 111.511 | -247.088 | 83.898 | 132.38 | 408.971 |
融资活动产生的现金 | -18.65 | -0.048 | 181.118 | -74.674 | -388.007 |
融资现金流项目 | -85.378 | -46.203 | -44.638 | -101.198 | -80.542 |
股票的发行(报废),净额 | 69.333 | 49.194 | 21.913 | 31.611 | 67.488 |
外汇效应 | 0.032 | -0.057 | -1.15 | 0.902 | -0.598 |
现金净变化 | 137.255 | -61.882 | 211.712 | -56.536 | -104.046 |
债务的发行(退还),净额 | -2.605 | -3.039 | 203.843 | -5.087 | -374.953 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 50.852 | 141.561 | 141.81 | 148.462 | 120.798 |
Cash From Operating Activities | -73.932 | 175.902 | 169.116 | 10.795 | -45.431 |
Cash From Operating Activities | 26.421 | 101.969 | 77.416 | 52.614 | 27.343 |
Deferred Taxes | -6.36 | -52.087 | -0.743 | 3.455 | 4.8 |
Non-Cash Items | 71.797 | 80.842 | 33.872 | -18.97 | -61.68 |
Cash Taxes Paid | 4.364 | 54.372 | 13.425 | 11.821 | 1.316 |
Cash Interest Paid | 1.437 | 10.281 | 6.575 | 5.137 | 1.422 |
Changes in Working Capital | -216.642 | -96.383 | -83.239 | -174.766 | -136.692 |
Cash From Investing Activities | -30.012 | -20.029 | 34.681 | 58.083 | 87.782 |
Capital Expenditures | -24.766 | -131.54 | -95.181 | -58.71 | -30.675 |
Other Investing Cash Flow Items, Total | -5.246 | 111.511 | 129.862 | 116.793 | 118.457 |
Cash From Financing Activities | -40.742 | -18.65 | -29.519 | -37.06 | -25.28 |
Financing Cash Flow Items | -60.897 | -85.378 | -71.75 | -65.431 | -32.949 |
Issuance (Retirement) of Stock, Net | 21.169 | 69.333 | 43.866 | 29.493 | 8.235 |
Issuance (Retirement) of Debt, Net | -1.014 | -2.605 | -1.635 | -1.122 | -0.566 |
Foreign Exchange Effects | 0.229 | 0.032 | -0.039 | 0.708 | 1.093 |
Net Change in Cash | -144.457 | 137.255 | 174.239 | 32.526 | 18.164 |
差價合約交易計算器
如果您在特定日期(選取一個日期)開立差價合約交易並在不同日期(選取一個日期)關閉交易,計算您的假設盈虧。
- 1:1
- 20
- 100
- 500
- 1000
- 10000
BioMarin Company profile
关于 BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc是一家生物技术公司。 公司为患有严重和危及生命的罕见疾病和医疗条件的人开发和商业化疗法。 公司的产品组合包括用于治疗各种疾病的商业产品以及多种临床和临床前候选产品。 公司的商业产品包括Aldurazyme(拉尼酶)、Brineura(cerliponase alfa)、Kuvan(sapropterin dihydrochloride)、Naglazyme(galsulfase)、Palynziq(pegvalias-pqpz)、Vimizim(elosulfase alpha)和Voxzogo(vosoritide)。 公司的管线包括治疗严重血友病A的Valoctocogene Roxaparvovec、治疗软骨病的Vosoritide、治疗苯丙酮尿症(PKU)的BMN 307和治疗遗传性血管性水肿(HAE)的BMN 331。
Industry: | Biopharmaceuticals |
105 Digital Dr
NOVATO
CALIFORNIA 94949
US
收入報表
- Annual
- Quarterly
人們也觀看
还在找一位您可以信任的经纪商吗?
加入成为全球610,000万多名交易者的一份子,选择利用Capital.com进行交易吧。